by McKesson Ventures | Mar 2, 2021 | Press Releases
GRAIL today announced a partnership with the health system Providence to offer Galleri, GRAIL’s multi-cancer early detection blood test. Providence, based in Renton, Wash., will offer Galleri as a complement to recommended single cancer screening tests. Providence...
by McKesson Ventures | Feb 23, 2021 | Portfolio News
GRAIL has entered an agreement with Quest Diagnostics to provide phlebotomy services in support of its multi-cancer early detection blood test. The test, called Galleri, is expected to go to market in the second quarter after its PATHFINDER multi-site interventional...
by McKesson Ventures | Jan 11, 2021 | Press Releases
GRAIL today announced a collaboration with global biopharmaceutical companies Amgen, AstraZeneca, and Bristol Myers Squibb to evaluate GRAIL’s methylation-based technology for the detection of minimal residual disease (MRD). Cancer MRD testing is used in clinical and...
by McKesson Ventures | Jan 11, 2021 | Press Releases
GRAIL has confirmed that it expects to introduce Galleri™, its multi-cancer early detection blood test, in the second quarter of 2021. In December 2020, GRAIL completed the enrollment of PATHFINDER, a prospective, 6,600-participant multi-site interventional study...
by McKesson Ventures | Sep 28, 2020 | Portfolio News
GRAIL and Illumina have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. In addition, GRAIL stockholders will receive future payments representing a tiered...
